Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
News|Articles|September 14, 2009
FDA issues early communication about ongoing safety review of orlistat
FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss.
Advertisement
FDA is reviewing reports of liver injury in patients treated with orlistat (prescription drug, Xenical; OTC drug, Alli) for obesity management or weight loss.
Between 1999 and 2008, 32 cases of serious liver injury in patients taking orlistat were reported to the agency. Of these cases, 27 included hospitalization and 6 resulted in liver failure. Jaundice, weakness, and stomach pain were the most commonly reported adverse events.
FDA’s analysis of these data is ongoing. The agency has advised that healthcare professionals should not change their prescribing practices at this time. Patients taking orlistat should consult a healthcare professional if they experience symptoms associated with the development of liver injury, including weakness or fatigue, jaundice, fever, and brown urine. Symptoms of abdominal pain, nausea, vomiting, light-colored stools, itching, and loss of appetite should also be reported.
Advertisement
Related to this article
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Navitus launched three modular options that let plan sponsors manage diabetes, weight, and lifestyle therapy access, cost, and outcomes with guaranteed ROI.
StarkRx has launched as a modular, cost-plus pharmacy benefit management company for self-funded employers using Judi Health’s PBM, Judi Rx, to administer claims.
Elevated levels of immunoglobulin G (IgG) drive “inflammaging” processes that take a toll on skin tissue as people age, according to research results reported by Japanese researchers. Reducing IgG may mitigate the loss of collagen and elastin.
ProAct Chief Operating Offier Deborah Dempsey says plan sponsors still lack the data and visibility to know whether they were shorted on a 340B claim.
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point drop in body mass index and improved mental health.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navitus launches GLP-1 drug management programs
2
New AACR report has found U.S. Cancer death rate dropped 35% since 1991
3
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
4
Judi Health, Employers Health team up to launch new PBM solution
5